These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The biology behind the new therapies for SLE. Ermann J; Bermas BL Int J Clin Pract; 2007 Dec; 61(12):2113-9. PubMed ID: 17997810 [TBL] [Abstract][Full Text] [Related]
5. [Rituximab therapy for severe pediatric systemic lupus erythematosus]. Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822 [TBL] [Abstract][Full Text] [Related]
6. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers. Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434 [TBL] [Abstract][Full Text] [Related]
7. Update on emerging drug therapies for systemic lupus erythematosus. Mok CC Expert Opin Emerg Drugs; 2010 Mar; 15(1):53-70. PubMed ID: 20148712 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of systemic lupus erythematosus: myths, certainties and doubts]. Ruiz-Irastorza G; Danza A; Khamashta M Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892 [TBL] [Abstract][Full Text] [Related]
9. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Tew GW; Rabbee N; Wolslegel K; Hsieh HJ; Monroe JG; Behrens TW; Brunetta PG; Keir ME Lupus; 2010 Feb; 19(2):146-57. PubMed ID: 19946034 [TBL] [Abstract][Full Text] [Related]
10. Newer therapeutic approaches for systemic lupus erythematosus. Ginzler EM; Dvorkina O Rheum Dis Clin North Am; 2005 May; 31(2):315-28. PubMed ID: 15922148 [TBL] [Abstract][Full Text] [Related]
11. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Murdaca G; Colombo BM; Puppo F Autoimmun Rev; 2011 Nov; 11(1):56-60. PubMed ID: 21835271 [TBL] [Abstract][Full Text] [Related]
12. [Psychiatric manifestations of lupus erythematosus systemic and Sjogren's syndrome]. Ampélas JF; Wattiaux MJ; Van Amerongen AP Encephale; 2001; 27(6):588-99. PubMed ID: 11865567 [TBL] [Abstract][Full Text] [Related]
13. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943 [TBL] [Abstract][Full Text] [Related]
14. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Walsh M; Jayne D Kidney Int; 2007 Sep; 72(6):676-82. PubMed ID: 17609693 [TBL] [Abstract][Full Text] [Related]
15. Biologics in SLE: the current status. Rajadhyaksha AG; Mehra S; Nadkar MY J Assoc Physicians India; 2013 Apr; 61(4):262-7. PubMed ID: 24482965 [TBL] [Abstract][Full Text] [Related]
16. The future of lupus therapy modulating autoantigen recognition. Okamoto A; Fujio K; Yamamoto K Lupus; 2010 Oct; 19(12):1474-81. PubMed ID: 20947560 [TBL] [Abstract][Full Text] [Related]
17. New therapies for systemic lupus erythematosus: cellular targets. Looney RJ; Anolik J; Sanz I Rheum Dis Clin North Am; 2006 Feb; 32(1):201-15, xi. PubMed ID: 16504831 [TBL] [Abstract][Full Text] [Related]
18. Current role of rituximab in systemic lupus erythematosus. Mok CC Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652 [TBL] [Abstract][Full Text] [Related]
19. Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. Andreoli L; Fredi M; Nalli C; Reggia R; Lojacono A; Motta M; Tincani A J Autoimmun; 2012 May; 38(2-3):J197-208. PubMed ID: 22204899 [TBL] [Abstract][Full Text] [Related]